Clinical Trials
APEC1621B, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of JNJ-42756493 (Erdafitinib) in patients with relapsed pediatric solid tumors harboring FGFR1/2/3/4 alteration
Cancer Type
Multiple Sites
ClinicalTrials.gov Identifier
NCT03210714
Principal Investigator
Anne–Marie Langevin MD
For more information about this study
View DetailsAbout This Study
This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.